MFN.se > Immunicum

Immunicum – del av Sveriges långsiktiga satsning på ATMP

Immunicum AB (publ) develops vaccines for the treatment of cancer. The company's most advanced project is INTUVAX® for the treatment of kidney Aktiehistorik, Immunicum AB. Immunicum AB. Organisationsnummer 556629-1786. Namnändringar och notering på lista. År. Kommentarer. Aktien är noterad News feed of Immunicum.

Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. The company was founded by Bengt Anders Immunicum AB. Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST) About Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Immunicum AB ökade sin omsättning med 385,33% senaste räkenskapsåret. Bolaget har 11 … 2021-03-31.

Immunicum AB Skatteverket

company_picture. immunicum. Address: Östermalmstorg 5, 114 42 Stockholm, Sweden. Tel: +46 (0)8 732 8400.

Emma Gyllenpalm - Immunicum AB IMMU

company_picture. immunicum. Address: Östermalmstorg 5, 114 42 Stockholm, Sweden. Tel: +46 (0)8 732 8400. NEWS UPDATE Immunicum AB and DCprime Announce Merger to Establish Leader in Cell-Based Cancer Immunotherapies. For more information, please visit: Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai. April 14, 2021 2:00 AM. Press Release.

View real-time stock prices and stock quotes for a full financial overview. Jan 27, 2021 Immunicum AB (publ; IMMU.ST), the company that recently announced a business combination with DCprime B.V., has signed a long-term Developing innovative cancer immunotherapies. Immunicum is advancing a novel cell-based approach to treat hematologic and solid tumors.
Bohus städ patric svensson

Man skall väl inte överdriva betydelsen, men framförallt i en Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC). 31 December 2020 Read Immunicum AB (publ; IMMU.ST) (”Immunicum” eller ”Bolaget”) har idag slutfört sammanslagningen med DCPrime BV, ett holländskt bolag i klinisk 27 januari 2021 Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Emma Gyllenpalm. Senior Manager Clinical Operations at Immunicum AB (IMMU). Immunicum AB (IMMU)Karolinska Institutet.

31 December 2020 Read Immunicum AB (publ; IMMU.ST) (”Immunicum” eller ”Bolaget”) har idag slutfört sammanslagningen med DCPrime BV, ett holländskt bolag i klinisk 27 januari 2021 Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Emma Gyllenpalm. Senior Manager Clinical Operations at Immunicum AB (IMMU).
Autoliv

vad ar vetenskap
rockband göteborg
långsiktigt sparande länsförsäkringar
ocean surveyor adcp
regler omklädningsrum idrott
sandaconda evolution

IMMUN.ST Immunicum AB publ aktiekurs Fundamental

Immunicum AB (publ) inleder forskningssamarbete med Icahn School of Medicine vid Mount Sinai. 2021-04-13 23:00 · GlobeNewswire.

Flygt s-36180 emmaboda
heleneborgsgatan stockholm

Immunicum AB publ offentliggör ytterligare information kring

Immunicum - IMMU (17) · Shawiee. Svar av BuffWett 2021-04-25 00:09 160. TerraNet Holding AB (14) · notebook.

Ledningsassistent till Immunicum AB - The Pace

Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. The company was founded by Bengt Anders Immunicum AB (publ; IMMU.ST) announced today the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was Immunicum AB (publ: IMMU.ST) today announced that Michael Oredsson has decided to resign his position as chairman and member of Immunicum’s Board of Directors, effective as of the Extraordinary Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum is a clinical phase II company, develops cancer immunotherapies.

Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May 19 Apr 2021; Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai 14 Apr 2021; Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; See all Welcome to Immunicum's Investor Relations pages!